CN116406270A - 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合 - Google Patents

在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合 Download PDF

Info

Publication number
CN116406270A
CN116406270A CN202180075784.2A CN202180075784A CN116406270A CN 116406270 A CN116406270 A CN 116406270A CN 202180075784 A CN202180075784 A CN 202180075784A CN 116406270 A CN116406270 A CN 116406270A
Authority
CN
China
Prior art keywords
bedaquiline
weeks
combination
clarithromycin
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180075784.2A
Other languages
English (en)
Chinese (zh)
Inventor
黑泽健
S·马哈德万
C·坎比利
高忠石
S·L·F·罗森努
W·M·M·威尔姆斯
J·E·别文加
E·G·A·埃尔诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN116406270A publication Critical patent/CN116406270A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180075784.2A 2020-11-12 2021-11-10 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合 Pending CN116406270A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113149P 2020-11-12 2020-11-12
US63/113149 2020-11-12
PCT/EP2021/081193 WO2022101244A1 (en) 2020-11-12 2021-11-10 Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases

Publications (1)

Publication Number Publication Date
CN116406270A true CN116406270A (zh) 2023-07-07

Family

ID=78695693

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180075784.2A Pending CN116406270A (zh) 2020-11-12 2021-11-10 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合

Country Status (7)

Country Link
US (1) US20230346770A1 (https=)
EP (1) EP4243800A1 (https=)
JP (1) JP2023549605A (https=)
KR (1) KR20230107275A (https=)
CN (1) CN116406270A (https=)
TW (1) TW202233168A (https=)
WO (1) WO2022101244A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250169098A (ko) 2024-05-24 2025-12-02 주식회사 에이엔제이사이언스 티오펩타이드 화합물을 포함하는 비결핵 항산균 감염증의 예방, 개선 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110869004A (zh) * 2017-07-14 2020-03-06 詹森药业有限公司 长效配制品
WO2020144197A1 (en) * 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1527050T3 (da) 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
AU2005249231B2 (en) 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
UA97813C2 (uk) 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
LT3250182T (lt) * 2015-01-27 2023-07-10 Janssen Pharmaceutica Nv Dispersinės kompozicijos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110869004A (zh) * 2017-07-14 2020-03-06 詹森药业有限公司 长效配制品
WO2020144197A1 (en) * 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases

Also Published As

Publication number Publication date
WO2022101244A1 (en) 2022-05-19
JP2023549605A (ja) 2023-11-28
US20230346770A1 (en) 2023-11-02
EP4243800A1 (en) 2023-09-20
KR20230107275A (ko) 2023-07-14
TW202233168A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
Tapson et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial
JP2025081386A (ja) 非結核性抗酸菌症の処置における組合せ
JP5781606B2 (ja) インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
Schaaf et al. Antituberculosis drugs in children
Blasi et al. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis
CN117045657A (zh) 一种药物组合及其应用
US20200253959A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
CN116406270A (zh) 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
TW201919630A (zh) 用於治療ｈｉｖ感染及ａｉｄｓ之療程
Golia et al. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease
Cass et al. The bioavailability of the novel nonnucleoside reverse transcriptase inhibitor GW420867X is unaffected by food in healthy male volunteers
HK40096376A (zh) 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
Becker Atazanavir: improving the HIV protease inhibitor class
US11590154B2 (en) Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
HK40050798A (en) Combination in the treatment of nontuberculous mycobacterial diseases
CN119564683B (zh) 一种抗分枝杆菌感染的联合增效药物组合物
EP2705840A1 (en) Use of rifapentine in the treatment and/or prevention of active tuberculosis disease
WO2023107149A1 (en) Non-tuberculosis mycobacteria infection treatment
WO2023232838A1 (en) Bedaquiline for use in the treatment of leprosy
WO2025250560A1 (en) Methods for treating bronchiectasis
Gill et al. David W. Denning, Richard M. Tucker, John S. Hostetler

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096376

Country of ref document: HK